Company news

Botanix Pharmaceuticals Limited news in 2022

Botanix Pharmaceuticals Limited's news releases, calls and decks from 2022, newest first.

View company

Confirmation Sofpironium Bromide NDA Formally Under Review

December 7, 2022

Placement Completion and Results of Share Purchase Plan

November 28, 2022

Share Purchase Plan Opens

November 8, 2022

A$5 million Institutional Placement and Share Purchase Plan

October 30, 2022

Botanix receives A$3.7m R&D Tax Incentive Refund

October 25, 2022

BOT Announces Promotion and Focus on NDA Approval Readiness

October 20, 2022

Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea

October 12, 2022

BOT Submits FDA New Drug Application for Sofpironium Bromide

September 25, 2022

Issue of First $7.0m Tranche of A$7.5m Placement Completed

September 12, 2022

Botanix Completes Successful A$7.5m Placement

September 1, 2022

Preliminary Final Report

August 30, 2022

Quarterly activities report and Appendix 4C

July 29, 2022

Change of Director's Interest Notice * 3

July 7, 2022

Application for quotation of securities - BOT

July 7, 2022

NDA Filing Accelerated and Trials Fully Enrolled

July 6, 2022

Dermatology Asset Acquired to Accelerate Path to Revenue

May 4, 2022

Appendix 4C - Quarterly

April 28, 2022

FDA Qualified Infectious Disease Product Status for BTX 1801

April 27, 2022

Notification regarding unquoted securities - BOT

April 14, 2022

Decks in 2022